Compare Moderna, Inc. (MRNA) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Moderna, Inc. trades at $220.99 (market cap $78.65B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.93 (market cap $47.61B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| MRNA | TLT | |
|---|---|---|
Market Cap | $78.65B | $47.61B |
Volume | 37,373,437 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $203.46 | $92.06 |
52-Week Low | $22.36 | $77.11 |
Typical Hold Time | 59 Days | 83 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
TLT, the iShares 20+ Year Treasury Bond ETF, is trading at $77.83 with a 0.89% daily gain amid a challenging bond market environment. The ETF has declined 11% year-to-date and 46% over five years as Treasury yields reach multi-decade highs. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights significant bond market volatility with Treasury yields hitting levels not seen since 2007.
The outlook for TLT remains heavily dependent on interest rate direction, with current high yields presenting both income opportunity and continued price risk. Key risks include persistent inflation pressures and Federal Reserve policy uncertainty. Investors should weigh the attractive yield against potential further bond price declines if rates continue rising.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
